Torrent Pharmaceuticals has officially announced the launch of its semaglutide brands - Sembolic and Semalix - in India, offering both oral and injectable formulations. The company has achieved the distinction of being the first Indian pharmaceutical company to launch generic oral semaglutide, marking a significant milestone in India's diabetes and obesity treatment landscape.

Product Launch Details

The pharmaceutical company has introduced two branded formulations of semaglutide to address the growing need for metabolic disorder treatments:

Leadership Perspective

Amal Kelshikar, CEO – India Business at Torrent Pharma, emphasized the significance of this launch: "Metabolic disorders represent one of the most significant healthcare challenges in India with a significant portion of our population affected by Type-2 Diabetes. Our entry into the GLP-1 therapy segment reflects Torrent's commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices."

GLP-1 Therapy Segment

The launch expands Torrent's presence in the GLP-1 (glucagon-like peptide-1) receptor agonist category, which represents well-established prescription medications for managing type 2 diabetes and obesity. These medications work by enhancing insulin secretion, reducing glucagon levels, and helping regulate appetite. They have demonstrated effectiveness in decreasing haemoglobin A1c (HbA1c), promoting weight loss, and reducing cardiovascular event risks.

Company Profile

Torrent Pharmaceuticals operates as the flagship company of the Torrent Group, with annual revenues exceeding ₹11,500 crores and group revenues of approximately ₹45,000 crores. Following the JB Pharma acquisition, the company ranks 5th in the Indian Pharmaceuticals Market and maintains top 5 positions in cardiovascular, gastro intestinal, central nervous system, pain management, and cosmo-dermatology therapeutic segments.

The company maintains a specialty-focused approach with approximately 76% of its India revenues derived from chronic and sub-chronic therapies, while establishing itself as the number 1 Indian pharma company in Brazil and Germany.

Torrent Pharmaceuticals has announced its unaudited consolidated financial results for Q3FY26, demonstrating robust performance across all key markets. The pharmaceutical major delivered strong growth momentum, reinforcing its position in both domestic and international segments while progressing with its strategic acquisition of JB Chemicals & Pharmaceuticals Limited.

Board Meeting and Regulatory Compliance

The Board of Directors approved the financial results at their meeting held on February 13, 2026, which commenced at 02:00 pm and concluded at 04:30 pm. The company submitted its quarterly results under Regulation 33 of SEBI Listing Regulations to both BSE (Scrip Code: 500420) and NSE (Scrip Code: TORNTPHARM). The board also declared an interim dividend of ₹29 per equity share, representing 580% on the face value of ₹5 per share, expected to be paid on or around March 6, 2026.

Strong Quarterly Financial Performance

The company's Q3FY26 results showcase impressive growth across all geographical segments. Total consolidated revenue reached ₹3,303 crores, marking an 18% year-on-year increase from ₹2,809 crores in Q3FY25.

Profitability Metrics Show Strong Growth

The company achieved significant improvement in profitability metrics during Q3FY26. Net profit after tax reached ₹635 crores, representing a 26% year-on-year growth. Operating EBITDA stood at ₹1,088 crores, up 19% from the previous year, maintaining a healthy margin of 33%.

Nine-Month Performance Sustains Growth Momentum

For the nine-month period ended December 31, 2025, Torrent Pharmaceuticals maintained consistent growth across all segments. Total revenue for the period reached ₹9,783 crores, representing a 14% increase from ₹8,557 crores in the corresponding period of the previous year.

JB Pharma Acquisition Progress

The company has made significant progress in its acquisition of JB Chemicals & Pharmaceuticals Limited. Torrent Pharmaceuticals acquired a controlling stake representing 46.39% of JB Pharma's equity share capital and obtained control with effect from January 21, 2026. The company is in the process of obtaining requisite approvals from SEBI for the proposed scheme of merger. Upon merger, Torrent will issue 51 fully paid-up equity shares for every 100 shares held in JB Pharma.

Source: